DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for facial nerve disease — screening already-approved drugs against its 17-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFacial nerve disease maps to a 17-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for facial nerve disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein tyrosine phosphatase receptor type B (PTPRB) — PTPRB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet tert-butoxycarbonyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2I4G · 1.65 Å · ligand N-(TERT-BUTOXYCARBONYL)-L-TYROSYL-N-METHYL-4-(SULFOAMINO)-L-PHENYLALANINAMIDE (UA1). Experimental structure, not a prediction.
What the evidence adds up to
A 2004 retrospective study of six patients treated surgically for facial nerve tumours (four schwannomas, two haemangiomas) found that all six had alterations affecting facial functioning during the disease course, and all had some kind of deficit at the end of follow-up. Mean age was 29 years, range 16–46. Presenting symptoms included facial palsy in four patients, neurosensory hypoacusis in one, and tinnitus in one. Neural grafts were performed in three patients. The authors concluded that early diagnosis is needed to reduce facial sequelae after surgery, but no quantitative outcomes such as recovery rates or time to improvement were reported.
A 2013 review of facial nerve palsy management noted that the condition arises from many causes and that clinical presentation and severity vary widely. The review summarised radiologic studies of anatomy, development of grading schemes and software for clinical assessment, and a range of medical and surgical treatment options, some novel and some variants of older methods. No specific drug, device, or numerical outcome data were presented; the review emphasised that management must be individualised.
A 2025 narrative review on future innovations for facial nerve paralysis described negative physical and psychosocial effects including impaired respiration, articulation, oral competence, and corneal protection, leading to decreased quality of life and social isolation. The review discussed biomedical engineering and facial reanimation concepts but provided no original data, no drug names, and no quantitative results from any intervention.
A 2024 report on electropuncture and pharmacopuncture with homeopathic and allopathic drugs for peripheral facial nerve neuropathy in the long-term period described the methods and recommended their use in neurological rehabilitation practice. No sample size, no response rates, no survival data, and no comparative outcomes were given. The report did not specify which drugs were used or how effectiveness was measured.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Ophthalmology · 2013 · 10 citations
Current considerations in the management of facial nerve palsy
AbstractPURPOSE OF REVIEW: Facial nerve palsy is a potentially devastating condition that can arise from many different causes. Appropriate management is complicated by the wide spectrum of clinical presentation and disease severity that characterizes this condition. As such, recent studies have focused on augmenting our understanding of the underlying anatomy and pathophysiology of facial nerve palsy, while also exploring different treatment options. RECENT FINDINGS: There have been a multitude of radiologic investigations that have delineated anatomical considerations pertinent to facial neuropathy, whereas various grading schemes and software programs have been developed to facilitate the clinical assessment of patients. Furthermore, a wide variety of medical and surgical treatment options have been proposed - whereas some are variants of previously described methods, others represent novel approaches. SUMMARY: Appropriate management of facial nerve palsy is dependent on a multitude of factors and must be tailored to patients on an individual basis. The studies summarized in this article highlight the recent advancements geared toward refining the assessment and treatment of patients with facial neuropathy.
AbstractINTRODUCTION: Tumours originating in the facial nerve are extremely rare and their therapeutic approach requires the aid of specialists from a number of disciplines. AIMS: Our aim was to analyse the cases treated in our centre over a five-year period. PATIENTS AND METHODS: All the subjects submitted to surgical interventions to treat facial nerve tumours between January 1992 and December 1996 were evaluated retrospectively. Data recorded from all patients included age, sex, side affected, time prior to diagnosis, presenting symptom and symptoms observed at the time of diagnosis, previous history of disorders affecting the facial nerve and associated neurological symptoms. We also noted the location of the lesion, the surgical technique used, pathology findings, post-operative complications, length of post-operative stay in hospital, facial sequelae and surgical repair procedures used on the facial nerves involved in the intervention. RESULTS: Six cases, with a mean age of 29 years (range: 16-46 years), were treated. Three of the patients were males (50%). Symptoms of the disease included facial palsy (4), neurosensory hypoacusis (1) and tinnitus (1). All six individuals (100%) had alterations affecting facial functioning in the course of the disease. The pathological diagnosis was schwannoma in four cases and hemangioma in the other two. Neural grafts were carried out in three patients and some kind of deficit was observed at the end of the follow-up in all the cases. CONCLUSIONS: Facial nerve tumours are very infrequent. An early diagnosis is needed to diminish the facial sequelae following surgery performed to treat this clinical entity.
Future innovations for the treatment of facial nerve paralysis
AbstractFacial nerve injury and paralysis causes negative physical and psychosocial effects for afflicted patients. Impaired respiration, articulation, oral competence, as well as insufficient protection of the corneas may cause a markedly decreased quality of life and social isolation. The optimal management of underlying pathologies and the resulting symptoms is thus an ongoing topic of clinical and pre-clinical research and the optimal management of facial nerve injury is continuing to evolve. Recent technological advances have opened up exciting possibilities in this complex field, giving hope to treating physicians and afflicted patients alike. The present narrative review summarizes several concepts regarding biomedical engineering and facial reanimation with an overview of the current literature.
Modern Technologies and Scientific and Technological Progress · 2024 · 0 citations · open access
RESTORATIVE POSSIBILITIES OF USE OF ELECTRICAL AND PHARMACOPUNTURE IN THE TREATMENT OF PERIPHERAL NEUROPATHY OF THE FACIAL NERVE IN THE LONG-TERM PERIOD
AbstractThe possibilities of using electropuncture and pharmacopuncture methods with homeopathic and al-lopathic drugs for the treatment of patients in the long-term period of development of peripheral neu-ropathies of the facial nerve are described. The effectiveness of the treatment was assessed, and its implementation in neurological rehabilitation practice was recommended
International Journal of Homoeopathic Sciences · 2022 · 0 citations · open access
Trigeminal neuralgia (Tic Douloureux) and its Homoeopathic treatment
AbstractTrigeminal neuralgia is a disorder characterized by pain associated with paroxysm of facial muscles. It is a disorder of 5th cranial nerve. Trigeminal neuralgia is triggered by exposure to cold air, some simple activity like eating, drinking, brushing the teeth and mouth washing etc. Some time it is associated with facial trauma or dental procedure; blood vessels pressing against trigeminal nerve is a cause. Here we have also described about differential diagnosis, allopathic and homeopathic treatment. Also presented here with is one case of trigeminal neuralgia which is being treated with homeopathic medicine. The patient is much better in his complaints and is showing good improvement.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
